Physician profile
Lynn A Amarante
NPI 1568456564
$2,901.07
in general payments reported to CMS, 2019-2025
21 companies · $492 in 2025
The $492 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.82 · 2020: $403 · 2021: $545 · 2022: $597 · 2023: $455 · 2024: $387 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.53 | 2020-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $433.49 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $279.36 | 2020-2025 | Absorica Ld, Winlevi, Ilumya |
| Ucb, INC. | $271.47 | 2020-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $257.48 | 2020-2025 | Dupixent |
| Lilly USA, LLC | $185.22 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $165.66 | 2021-2025 | |
| Galderma Laboratories, L.P. | $90.25 | 2021-2025 | Nemluvio, Dysport |
| Pfizer INC. | $86.00 | 2020-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.02 | 2020-2022 | |
| Incyte Corporation | $47.68 | 2021-2024 | Opzelura |
| Janssen Biotech, INC. | $40.93 | 2020-2021 | |
| Nabriva Therapeutics, Plc | $38.84 | 2021-2022 | |
| Amgen INC. | $38.70 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.15 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $29.86 | 2023 | Vtama |
| Dermira, INC. | $29.45 | 2020 | |
| Vyne Pharmaceuticals INC. | $24.66 | 2021 | |
| Almirall LLC | $22.82 | 2019 | |
| Arcutis Biotherapeutics, INC. | $18.42 | 2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lynn Amarante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.